https://www.ono-usa.com/
ONO PHARMA USA, INC. is the US subsidiary of ONO PHARMACEUTICAL CO, LTD., an R&D-oriented pharmaceutical company founded in 1717, with headquarters in Osaka, Japan. Throughout its 300 year history, ONO has been committed to Challenging the Unknown, to deliver novel medicines to patients with high unmet medical needs. Today, ONO has a growing pipeline of innovative therapeutics across four areas of focus: Oncology, Immunology, Neurology, and Specialty Medicine.
ONO PHARMA USA, INC. is pursuing the clinical development of new drug candidates and aiming to commercialize in the US. ONO PHARMA USA, INC. was established as a US subsidiary of Ono Pharmaceutical Co., Ltd. (ONO) in 1998. ONO was founded in Osaka, Japan, in 1717. ONO is an R&D-oriented pharmaceutical company committed to discovering and developing “first-in-class” medicines, like nivolumab, an anti-PD-1 antibody drug, focusing on oncology, immunology, neurology, and specialty research.